Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Shareholder Meeting (November 2023)
10 slides from Kazia Therapeutics's shareholder meeting presentation, Nov 30, 2023
Slide 1: 2023 Annual General Meeting: R&D and Clinical Overview
2023 Annual General Meeting R&D and Clinical Overview John Friend, MD Chief Executive Officer 30 November 2023 1NASDAQ: KZIA | Twitter: @KaziaTx
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All state
Slide 3: Kazia R&D and clinical advancements during 2023 steady and positive
Kazia R&D and clinical advancements during 2023 has been steady and positive Paxalisib Institution Disease/Study Key Developments Month ANZCHOG Molecular-driven childhood & adolescent cancer Clinical Trial (OPTIMISE) collaboration March AACR Melanoma, DMG/DIPG & AT/RT Preclinical data presented Apri
Slide 4: Paxalisib clinical study status - Pediatric Brain Cancer Pillar
Paxalisib clinical study status - Pediatric Brain Cancer Pillar Pediatric Brain Cancer Studies Protocol Number Study Name Study Update PNOC022 Study Name: A Combination Therapy Trial using an Study Start Date: October 2021 Adaptive Platform Design for Children and Young Adults Total enrolled to date
Slide 5: Paxalisib clinical study status - Adult Primary Brain Cancer
Paxalisib clinical study status – Adult Primary Brain Cancer Adult Brain Cancer Studies Protocol Number Study Name Study Update GCAR-7213 GBM AGILE Global Adaptive Trial Master Protocol: An International, Data in final stages of cleaning and Seamless Phase II/III Response Adaptive Randomization Plat
Slide 6: Paxalisib clinical study status - Adult Brain Metastases
Paxalisib clinical study status – Adult Brain Metastases Adult Brain Metastases Studies Protocol Number Study Name Study Update 19-359 Memorial Sloan Kettering Cancer Center - GDC-0084 With Radiation Study Start Date: November 2019 Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases
Slide 7: Paxalisib - Research and Development
Paxalisib - Research and Development QIMR – Professor Sudha Rao University Utah – Professor Sheri Holman • Key Development • Key Development – Evaluating PI3K inhibition as an immune modulator of – PI3K-AKT-mTOR pathway alterations are critical the tumor and tumor microenvironment component of prima
Slide 8: EVT801 - Phase 1 clinical study continues to enroll as planned
EVT801 - Phase 1 clinical study continues to enroll as planned EVT801 Clinical Study Protocol Number Study Name Study Update KZA 0801-101 A Phase 1, First in Human, Open Label Study to To date 28 patients included in the study Assess the Safety, Tolerability, and Pharmacokinetics • 22 patients treat
Slide 9: Looking to 2024 and beyond…
Looking to 2024 and beyond… • Engaging new investors – Short term (6-month) Promissory note USD $500,000 from new European investor • Continue discussions and engagement with leading US investment banks • Explore strategic and alternative opportunities for paxalisib and EVT-801 • Opportunistic use o
Slide 10: www.kaziatherapeutics.com [email protected]
www.kaziatherapeutics.com [email protected]
Kazia Therapeutics — Shareholder Meeting (November 2023) on 6ix